KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $41.2 million.

  • Edwards Lifesciences' Share-based Compensation fell 213.78% to $41.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.6 million, marking a year-over-year decrease of 651.77%. This contributed to the annual value of $162.3 million for FY2024, which is 1642.75% up from last year.
  • Latest data reveals that Edwards Lifesciences reported Share-based Compensation of $41.2 million as of Q3 2025, which was down 213.78% from $37.5 million recorded in Q2 2025.
  • Edwards Lifesciences' 5-year Share-based Compensation high stood at $44.6 million for Q1 2024, and its period low was $24.2 million during Q4 2021.
  • Its 5-year average for Share-based Compensation is $34.6 million, with a median of $32.6 million in 2023.
  • As far as peak fluctuations go, Edwards Lifesciences' Share-based Compensation soared by 2914.11% in 2024, and later tumbled by 1457.86% in 2025.
  • Edwards Lifesciences' Share-based Compensation (Quarter) stood at $24.2 million in 2021, then rose by 15.29% to $27.9 million in 2022, then grew by 9.32% to $30.5 million in 2023, then increased by 3.93% to $31.7 million in 2024, then rose by 29.97% to $41.2 million in 2025.
  • Its Share-based Compensation was $41.2 million in Q3 2025, compared to $37.5 million in Q2 2025 and $40.2 million in Q1 2025.